Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback